Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: Interim analysis of a phase II study of the GCLLSG and fcgcll/MW

This article has no abstract
Epistemonikos ID: 948b08842c73baa2c9cdc4e9bf77efdadfb07421
First added on: Feb 05, 2025